Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration

Inclusion Criteria: \- Non-permanent atrial fibrillation documented on a 12 lead ECG, TTM or Holter monitor within the last 12 months Low Burden Paroxysmal - ≥2 episodes of AF over the past 12 months; Episodes terminate spontaneously within 7 days or via cardioversion within 48 hours of onset. High Burden Paroxysmal - ≥4 episodes of AF over the past 6 months, with ≥2 episodes \>6 hours in duration; Episodes terminate spontaneously within 7 days or via cardioversion within 48 hours of onset. Early Persistent - ≥2 episodes of AF over the past 12 months; Episodes are successfully terminated via cardioversion within 7 days of onset. * Age of 18 years or older on the date of consent * Candidate for ablation based on AF that is symptomatic and refractory (ineffective or intolerant) to at least one class 1 or 3 antiarrhythmic * Continuous anticoagulation with warfarin (INR 2-3), low molecular weight heparin, or a novel oral antithrombotic (dabigatran, apixaban, rivaroxaban) for ≥4 weeks prior to the ablation; or a TEE that excludes LA thrombus ≤48 hours before ablation * Informed Consent Form Exclusion Criteria: * Previous left atrial (LA) ablation or LA surgery * Pre-existing pulmonary vein stenosis or PV stent * Pre-existing hemidiaphragmatic paralysis * Contraindication to anticoagulation or radiocontrast materials * Anteroposterior LA diameter greater than 5.5 cm by TTE * Cardiac valve prosthesis * Clinically significant (moderately-severe, or severe) mitral valve regurgitation or stenosis * Myocardial infarction, PCI / PTCA, or coronary artery stenting during the 3-month period preceding the consent date * Cardiac surgery during the three-month interval preceding the consent date * Significant congenital heart defect (including atrial septal defects or PV abnormalities but not including PFO) * NYHA class III or IV congestive heart failure * Left ventricular ejection fraction (LVEF) less than 35% * Hypertrophic cardiomyopathy * Significant CKD (eGFR \<30 mL/min/m2) * Uncontrolled hyperthyroidism * Cerebral ischemic event (strokes or TIAs) during the six-month interval preceding the consent date * Subject known to be pregnant * Life expectancy less than one (1) year * Currently participating or anticipated to participate in any other clinical trial of a drug, device or biologic during the duration of this study * Unwilling or unable to comply fully with study procedures and follow-up